BioWorld

March 5, 2004

Inhibitex Files For IPO; Veronate Slated To Start Phase III In 2004

Inhibitex Inc. joined the ranks of private biotech companies looking to take advantage of a more receptive market with an initial public offering filing aimed at raising $86.25 million. (BioWorld Today) Read More

CTI Cleared For Pixantrone Trial; Strong Pipeline Backs NHL Drug

Legislation Could Help Patent Office Keep Fees, Add To Staff

After Pulling IPO, Acorda Raises $11.5M Through Private Round

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...